SJLB mice develop tauopathy-induced parkinsonism

Neuroscience Letters

Volumn 473, Issue 3, 2010, Pages 182-185

  Takenokuchi, Mariko ^a   Kadoyama, Keiichi ^a   Chiba, Shunmei ^b   Sumida, Miho ^c   Matsuyama, Shogo ^a   Saigo, Katsuyasu ^a   Taniguchi, Taizo ^a,c  

^a HIMEJI DOKKYO UNIVERSITY   (Japan)

^b ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Behavioral and Medical Sciences Research Consortium   (Japan)

Author keywords

Behavioral analysis; FTDP 17; Parkinsonism; Tauopathy; Transgenic mouse

Indexed keywords

DOPAMINE; TAU PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DEMENTIA; DISEASE COURSE; DISEASE SEVERITY; MOTOR DYSFUNCTION; MOUSE; MOUSE STRAIN; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; SYMPTOM; TAUOPATHY;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; MICE; MICE, TRANSGENIC; MUTATION; PARKINSONIAN DISORDERS; TAU PROTEINS; TAUOPATHIES;

EID: 77950339340     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2010.02.032     Document Type: Article

References (30)

1. Allen B., Ingram E., Takao M., Smith M.J., Jakes R., Virdee K., Yoshida H., Holzer M., Craxton M., Emson P.C., Atzori C., Migheli A., Crowther R.A., Ghetti B., Spillantini M.G., Goedert M. Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J. Neurosci. 2002, 22:9340-9351.
2. Arvanitakis Z., Witte R.J., Dickson D.W., Tsuboi Y., Uitti R.J., Slowinski J., Hutton M.L., Lin S.C., Boeve B.F., Cheshire W.P., Pooley R.A., Liss J.M., Caviness J.N., Strongosky A.J., Wszolek Z.K. Clinical-pathologic study of biomarkers in FTDP-17 (PPND family with N279K tau mutation). Parkinsonism Relat. Disord. 2007, 13:230-239.
3. Clark L.N., Poorkaj P., Wszolek Z., Geschwind D.H., Nasreddine Z.S., Miller B., Li D., Payami H., Awert F., Markopoulou K., Andreadis A., D'Souza I., Lee V.M., Reed L., Trojanowski J.Q., Zhukareva V., Bird T., Schellenberg G., Wilhelmsen K.C. Pathogenic implications of mutations in the tau gene in pallido-ponto-nigral degeneration and related neurodegenerative disorders linked to chromosome 17. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:13103-13107.
4. Ebneth A., Godemann R., Stamer K., Illenberger S., Trinczek B., Mandelkow E. Overexpression of tau protein inhibits kinesin-dependent trafficking of vesicles, mitochondria, and endoplasmic reticulum: implications for Alzheimer's disease. J. Cell Biol. 1998, 143:777-794.
5. Fearnley J.M., Lees A.J. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991, 114(Pt 5):2283-2301.
6. Fernagut P.O., Diguet E., Labattu B., Tison F. A simple method to measure stride length as an index of nigrostriatal dysfunction in mice. J. Neurosci. Methods 2002, 113:123-130.
7. Ghetti B., Piccardo P., Spillantini M.G., Ichimiya Y., Porro M., Perini F., Kitamoto T., Tateishi J., Seiler C., Frangione B., Bugiani O., Giaccone G., Prelli F., Goedert M., Dlouhy S.R., Tagliavini F. Vascular variant of prion protein cerebral amyloidosis with tau-positive neurofibrillary tangles: the phenotype of the stop codon 145 mutation in PRNP. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:744-748.
8. Ghetti B., Tagliavini F., Masters C.L., Beyreuther K., Giaccone G., Verga L., Farlow M.R., Conneally P.M., Dlouhy S.R., Azzarelli B., Bugiani O. Gerstmann-Sträussler-Scheinker disease. II. Neurofibrillary tangles and plaques with PrP-amyloid coexist in an affected family. Neurology 1989, 39:1453-1461.
9. Gotz J., Chen F., Barmettler R., Nitsch R.M. Tau filament formation in transgenic mice expressing P301L tau. J. Biol. Chem. 2001, 276:529-534.
10. Gotz J., Tolnay M., Barmettler R., Chen F., Probst A., Nitsch R.M. Oligodendroglial tau filament formation in transgenic mice expressing G272V tau. Eur. J. Neurosci. 2001, 13:2131-2140.
11. Hsiao K., Dlouhy S.R., Farlow M.R., Cass C., Da Costa M., Conneally P.M., Hodes M.E., Ghetti B., Prusiner S.B. Mutant prion proteins in Gerstmann-Sträussler-Scheinker disease with neurofibrillary tangles. Nat. Genet. 1992, 1:68-71.
12. Hutton M., Lendon C.L., Rizzu P., Baker M., Froelich S., Houlden H., Pickering-Brown S., Chakraverty S., Isaacs A., Grover A., Hackett J., Adamson J., Lincoln S., Dickson D., Davies P., Petersen R.C., Stevens M., de Graaff E., Wauters E., van Baren J., Hillebrand M., Joosse M., Kwon J.M., Nowotny P., Che L.K., Norton J., Morris J.C., Reed L.A., Trojanowski J., Basun H., Lannfelt L., Neystat M., Fahn S., Dark F., Tannenberg T., Dodd P.R., Hayward N., Kwok J.B., Schofield P.R., Andreadis A., Snowden J., Craufurd D., Neary D., Owen F., Oostra B.A., Hardy J., Goate A., van Swieten J., Mann D., Lynch T., Heutink P. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998, 393:702-705.
13. Ingram E.M., Spillantini M.G. Tau gene mutations: dissecting the pathogenesis of FTDP-17. Trends Mol. Med. 2002, 8:555-562.
14. Lewis J., McGowan E., Rockwood J., Melrose H., Nacharaju P., Van Slegtenhorst M., Gwinn-Hardy K., Paul Murphy M., Baker M., Yu X., Duff K., Hardy J., Corral A., Lin W.L., Yen S.H., Dickson D.W., Davies P., Hutton M. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat. Genet. 2000, 25:402-405.
15. Matsuura K., Kabuto H., Makino H., Ogawa N. Pole test is a useful method for evaluating the mouse movement disorder caused by striatal dopamine depletion. J. Neurosci. Methods 1997, 73:45-48.
16. Morris M.E., Iansek R., Matyas T.A., Summers J.J. The pathogenesis of gait hypokinesia in Parkinson's disease. Brain 1994, 117(Pt 5):1169-1181.
17. Nakashima K., Shimoyama R., Yokoyama Y., Takahashi K. Auditory effects on the electrically elicited blink reflex in patients with Parkinson's disease. Electroencephalogr. Clin. Neurophysiol. 1993, 89:108-112.
18. Ogawa N., Mizukawa K., Hirose Y., Kajita S., Ohara S., Watanabe Y. MPTP-induced parkinsonian model in mice: biochemistry, pharmacology and behavior. Eur. Neurol. 1987, 26(Suppl. 1):16-23.
19. Ohno Y., Ishida K., Ikeda K., Ishibashi T., Okada K., Nakamura M. Evaluation of bradykinesia induction by SM-9018, a novel 5-HT2 and D2 receptor antagonist, using the mouse pole test. Pharmacol. Biochem. Behav. 1994, 49:19-23.
20. Pennanen L., Welzl H., D'Adamo P., Nitsch R.M., Gotz J. Accelerated extinction of conditioned taste aversion in P301L tau transgenic mice. Neurobiol. Dis. 2004, 15:500-509.
21. Poorkaj P., Bird T.D., Wijsman E., Nemens E., Garruto R.M., Anderson L., Andreadis A., Wiederholt W.C., Raskind M., Schellenberg G.D. Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann. Neurol. 1998, 43:815-825.
22. Schicatano E.J., Peshori K.R., Gopalaswamy R., Sahay E., Evinger C. Reflex excitability regulates prepulse inhibition. J. Neurosci. 2000, 20:4240-4247.
23. Spillantini M.G., Murrell J.R., Goedert M., Farlow M.R., Klug A., Ghetti B. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:7737-7741.
24. Swerdlow N.R., Geyer M.A., Braff D.L. Neural circuit regulation of prepulse inhibition of startle in the rat: current knowledge and future challenges. Psychopharmacology (Berl) 2001, 156:194-215.
25. Tagliavini F., Giaccone G., Prelli F., Verga L., Porro M., Trojanowski J.Q., Farlow M.R., Frangione B., Ghetti B., Bugiani O. A68 is a component of paired helical filaments of Gerstmann-Sträussler-Scheinker disease, Indiana kindred. Brain Res. 1993, 616:325-329.
26. Tanemura K., Akagi T., Murayama M., Kikuchi N., Murayama O., Hashikawa T., Yoshiike Y., Park J.M., Matsuda K., Nakao S., Sun X., Sato S., Yamaguchi H., Takashima A. Formation of filamentous tau aggregations in transgenic mice expressing V337M human tau. Neurobiol. Dis. 2001, 8:1036-1045.
27. Taniguchi T., Doe N., Matsuyama S., Kitamura Y., Mori H., Saito N., Tanaka C. Transgenic mice expressing mutant (N279K) human tau show mutation dependent cognitive deficits without neurofibrillary tangle formation. FEBS Lett. 2005, 579:5704-5712.
28. Taniguchi T., Matsuyama S., Minoura K., Iso H., Sasaki M., Tomoo K., Ishida T., Mori H., Tanaka C. Learning deficits in N279K tau transgenic mice and an assembly model of tau protein. Molecular Neurobiology of Alzheimer Disease and Related Disorders 2004, 183-194. Karger, Freiburg. M. Takeda, T. Tanaka, R. Cacabelos (Eds.).
29. Tatebayashi Y., Miyasaka T., Chui D.H., Akagi T., Mishima K., Iwasaki K., Fujiwara M., Tanemura K., Murayama M., Ishiguro K., Planel E., Sato S., Hashikawa T., Takashima A. Tau filament formation and associative memory deficit in aged mice expressing mutant (R406W) human tau. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:13896-13901.
30. Xu K., Xu Y.H., Chen J.F., Schwarzschild M.A. Caffeine's neuroprotection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity shows no tolerance to chronic caffeine administration in mice. Neurosci. Lett. 2002, 322:13-16.